Quality control is an integral and critical part of biologics development and manufacturing, encompassing both contamination control to data integrity. However, the quality of biologics can be impacted by minor variations in manufacturing processes, a problem seen often during the COVID-19 pandemic.

This article explores the changes made by biopharmaceutical companies and CDMOs to adapt to the “new normal”, drawing from the experiences of quality control experts including Natasha Rivas, Vice President of Quality and Regulatory, at Genezen.

Read the full article here: A New View on Quality Control?